PAVmed Inc. (PAVM)
| Market Cap | 87.61M |
| Revenue (ttm) | 689,000 |
| Net Income (ttm) | -58.06M |
| Shares Out | 87.97M |
| EPS (ttm) | -0.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,172,883 |
| Open | 1.040 |
| Previous Close | 1.050 |
| Day's Range | 0.975 - 1.090 |
| 52-Week Range | 0.820 - 9.700 |
| Beta | 0.24 |
| Analysts | Buy |
| Price Target | 6.12 (+514.5%) |
| Earnings Date | Aug 11, 2022 |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo,... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is 6.12, which is an increase of 514.52% from the latest price.
News
PAVmed PAVmed Provides Business Update and Preliminary First Quarter 2022 Financial Results
NEW YORK--(BUSINESS WIRE)---- $PAVM #PAVmed--PAVmed provides business update and preliminary first quarter 2022 financial results.
3 Short Squeeze Penny Stocks To Buy For Under $5 This Week
Short squeeze penny stocks to watch this week. The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
3 Short Squeeze Penny Stocks To Buy For Under $5 This Week
Short squeeze penny stocks to watch this week. The post 3 Short Squeeze Penny Stocks To Buy For Under $5 This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PAVmed Announces Procedural Update on its Settlement of a Previously Disclosed Class Action Lawsuit
NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, today announced a procedural update...
PAVmed to Hold a Business Update Conference Call on May 12, 2022
NEW YORK--(BUSINESS WIRE)---- $PAVM #businessupdate--PAVmed to hold a Business Update Conference Call on May 12, 2022.
PAVmed Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
NEW YORK--(BUSINESS WIRE)---- $PAVM #earnings--PAVmed provides business update and preliminary fourth quarter and full year 2021 financial results.
PAVmed Highlights First-In-Human Implantations of its PortIO Infusion System
PAVmed Inc (NASDAQ: PAVM) announced the successful implantation of its PortIO Intraosseous Infusion System in three patients as part of a first-in-human (FIH) clinical study of up to 40 patients. No com...
PAVmed Announces Successful First-in-Human Implantations of its PortIO™ Intraosseous Infusion System
NEW YORK--(BUSINESS WIRE)---- $PAVM #PortIO--PAVmed announces successful first-in-human implantations of its PortIO™ Intraosseous Infusion System.
PAVmed Subsidiary Veris Health Launches World-Class Technology Advisory Board
NEW YORK--(BUSINESS WIRE)---- $PAVM #DigitalHealth--PAVmed subsidiary Veris Health launches world-class technology advisory board.
PAVmed to Hold a Business Update Conference Call on March 29, 2022
NEW YORK--(BUSINESS WIRE)---- $PAVM #Healthcare--PAVmed to hold a business update conference call on March 29, 2022.
Why PAVmed Stock Plummeted on Wednesday
News of a fresh round of capital raising seems to be making some investors ill.
Veris Health Showcased in PAVmed Digital Health Virtual Investor Event
NEW YORK--(BUSINESS WIRE)---- $PAVM--Veris Health showcased in PAVmed Digital Health Virtual Investor Event.
PAVmed Digital Health Subsidiary Veris Health Appoints Sunny Webb as Chief Technology Officer
NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed Digital Health Subsidiary Veris Health appoints Sunny Webb as Chief Technology Officer.
PAVM Stock: One Big Reason Why PAVmed Is Plunging Today
Today, a relatively disappointing start to trading for a PAVmed subsidiary, Lucid Diagnostics, is driving some bearish price action. The post PAVM Stock: One Big Reason Why PAVmed Is Plunging Today appe...
Lucid Diagnostics Announces Pricing of Initial Public Offering
NEW YORK--(BUSINESS WIRE)---- $LUCD--Lucid Diagnostics announces pricing of Initial Public Offering.
PAVmed Acquires EsophaCap Manufacturer CapNostics LLC
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed acquires EsophaCap manufacturer CapNostics LLC.
PAVmed to Host Digital Health Virtual Investor Event
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed to Host Digital Health Virtual Investor Event, Veris Health: Bringing Digital Health to Cancer Care.
Why PAVmed Shares Are Trading Higher Today
PAVmed Inc (NASDAQ: PAVM) is trading higher Thursday after the company announced its majority-owned subsidiary, Lucid Diagnostics, filed a registration statement for a proposed initial public offering. ...
These 2 Nasdaq Small Caps Just Got Big Boosts
In a rising market, these companies looked especially impressive.
PAVmed Subsidiary, Lucid Diagnostics, Files Registration Statement for Proposed Initial Public Offering
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary, Lucid Diagnostics, files registration statement for proposed initial public offering.
PAVmed Subsidiary Veris Health Joins Microsoft for Startups Global Program and Engages Loka as Software Development P...
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Veris Health joins Microsoft for startups global program and engages Loka as software development partner.
PAVmed to Participate in September Investor and MedTech Conferences
NEW YORK--(BUSINESS WIRE)---- $PAVM--PAVmed to participate in September investor and MedTech conferences.
Why Shares of PAVmed Were Down This Morning
Investors are growing impatient about a planned spinoff.
PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results. Conference call to be held today at 4:30 PM EDT.
PAVmed Subsidiary Lucid Diagnostics Launches First Lucid Test Centers
NEW YORK--(BUSINESS WIRE)---- $pavm--PAVmed subsidiary Lucid Diagnostics launches first Lucid test centers. Patients undergoing esophageal precancer testing in Phoenix metro area.